Tag Archives: joint

#432027 We Read This 800-Page Report on the ...

The longevity field is bustling but still fragmented, and the “silver tsunami” is coming.

That is the takeaway of The Science of Longevity, the behemoth first volume of a four-part series offering a bird’s-eye view of the longevity industry in 2017. The report, a joint production of the Biogerontology Research Foundation, Deep Knowledge Life Science, Aging Analytics Agency, and Longevity.International, synthesizes the growing array of academic and industry ventures related to aging, healthspan, and everything in between.

This is huge, not only in scale but also in ambition. The report, totally worth a read here, will be followed by four additional volumes in 2018, covering topics ranging from the business side of longevity ventures to financial systems to potential tensions between life extension and religion.

And that’s just the first step. The team hopes to publish updated versions of the report annually, giving scientists, investors, and regulatory agencies an easy way to keep their finger on the longevity pulse.

“In 2018, ‘aging’ remains an unnamed adversary in an undeclared war. For all intents and purposes it is mere abstraction in the eyes of regulatory authorities worldwide,” the authors write.

That needs to change.

People often arrive at the field of aging from disparate areas with wildly diverse opinions and strengths. The report compiles these individual efforts at cracking aging into a systematic resource—a “periodic table” for longevity that clearly lays out emerging trends and promising interventions.

The ultimate goal? A global framework serving as a road map to guide the burgeoning industry. With such a framework in hand, academics and industry alike are finally poised to petition the kind of large-scale investments and regulatory changes needed to tackle aging with a unified front.

Infographic depicting many of the key research hubs and non-profits within the field of geroscience.
Image Credit: Longevity.International
The Aging Globe
The global population is rapidly aging. And our medical and social systems aren’t ready to handle this oncoming “silver tsunami.”

Take the medical field. Many age-related diseases such as Alzheimer’s lack effective treatment options. Others, including high blood pressure, stroke, lung or heart problems, require continuous medication and monitoring, placing enormous strain on medical resources.

What’s more, because disease risk rises exponentially with age, medical care for the elderly becomes a game of whack-a-mole: curing any individual disease such as cancer only increases healthy lifespan by two to three years before another one hits.

That’s why in recent years there’s been increasing support for turning the focus to the root of the problem: aging. Rather than tackling individual diseases, geroscience aims to add healthy years to our lifespan—extending “healthspan,” so to speak.

Despite this relative consensus, the field still faces a roadblock. The US FDA does not yet recognize aging as a bona fide disease. Without such a designation, scientists are banned from testing potential interventions for aging in clinical trials (that said, many have used alternate measures such as age-related biomarkers or Alzheimer’s symptoms as a proxy).

Luckily, the FDA’s stance is set to change. The promising anti-aging drug metformin, for example, is already in clinical trials, examining its effect on a variety of age-related symptoms and diseases. This report, and others to follow, may help push progress along.

“It is critical for investors, policymakers, scientists, NGOs, and influential entities to prioritize the amelioration of the geriatric world scenario and recognize aging as a critical matter of global economic security,” the authors say.

Biomedical Gerontology
The causes of aging are complex, stubborn, and not all clear.

But the report lays out two main streams of intervention with already promising results.

The first is to understand the root causes of aging and stop them before damage accumulates. It’s like meddling with cogs and other inner workings of a clock to slow it down, the authors say.

The report lays out several treatments to keep an eye on.

Geroprotective drugs is a big one. Often repurposed from drugs already on the market, these traditional small molecule drugs target a wide variety of metabolic pathways that play a role in aging. Think anti-oxidants, anti-inflammatory, and drugs that mimic caloric restriction, a proven way to extend healthspan in animal models.

More exciting are the emerging technologies. One is nanotechnology. Nanoparticles of carbon, “bucky-balls,” for example, have already been shown to fight viral infections and dangerous ion particles, as well as stimulate the immune system and extend lifespan in mice (though others question the validity of the results).

Blood is another promising, if surprising, fountain of youth: recent studies found that molecules in the blood of the young rejuvenate the heart, brain, and muscles of aged rodents, though many of these findings have yet to be replicated.

Rejuvenation Biotechnology
The second approach is repair and maintenance.

Rather than meddling with inner clockwork, here we force back the hands of a clock to set it back. The main example? Stem cell therapy.

This type of approach would especially benefit the brain, which harbors small, scattered numbers of stem cells that deplete with age. For neurodegenerative diseases like Alzheimer’s, in which neurons progressively die off, stem cell therapy could in theory replace those lost cells and mend those broken circuits.

Once a blue-sky idea, the discovery of induced pluripotent stem cells (iPSCs), where scientists can turn skin and other mature cells back into a stem-like state, hugely propelled the field into near reality. But to date, stem cells haven’t been widely adopted in clinics.

It’s “a toolkit of highly innovative, highly invasive technologies with clinical trials still a great many years off,” the authors say.

But there is a silver lining. The boom in 3D tissue printing offers an alternative approach to stem cells in replacing aging organs. Recent investment from the Methuselah Foundation and other institutions suggests interest remains high despite still being a ways from mainstream use.

A Disruptive Future
“We are finally beginning to see an industry emerge from mankind’s attempts to make sense of the biological chaos,” the authors conclude.

Looking through the trends, they identified several technologies rapidly gaining steam.

One is artificial intelligence, which is already used to bolster drug discovery. Machine learning may also help identify new longevity genes or bring personalized medicine to the clinic based on a patient’s records or biomarkers.

Another is senolytics, a class of drugs that kill off “zombie cells.” Over 10 prospective candidates are already in the pipeline, with some expected to enter the market in less than a decade, the authors say.

Finally, there’s the big gun—gene therapy. The treatment, unlike others mentioned, can directly target the root of any pathology. With a snip (or a swap), genetic tools can turn off damaging genes or switch on ones that promote a youthful profile. It is the most preventative technology at our disposal.

There have already been some success stories in animal models. Using gene therapy, rodents given a boost in telomerase activity, which lengthens the protective caps of DNA strands, live healthier for longer.

“Although it is the prospect farthest from widespread implementation, it may ultimately prove the most influential,” the authors say.

Ultimately, can we stop the silver tsunami before it strikes?

Perhaps not, the authors say. But we do have defenses: the technologies outlined in the report, though still immature, could one day stop the oncoming tidal wave in its tracks.

Now we just have to bring them out of the lab and into the real world. To push the transition along, the team launched Longevity.International, an online meeting ground that unites various stakeholders in the industry.

By providing scientists, entrepreneurs, investors, and policy-makers a platform for learning and discussion, the authors say, we may finally generate enough drive to implement our defenses against aging. The war has begun.

Read the report in full here, and watch out for others coming soon here. The second part of the report profiles 650 (!!!) longevity-focused research hubs, non-profits, scientists, conferences, and literature. It’s an enormously helpful resource—totally worth keeping it in your back pocket for future reference.

Image Credit: Worraket / Shutterstock.com Continue reading

Posted in Human Robots

#431900 Artificial muscles power up with new ...

Scientists are one step closer to artificial muscles. Orthotics have come a long way since their initial wood and strap designs, yet innovation lapsed when it came to compensating for muscle power—until now. A collaborative research team has designed a wearable robot to support a person's hip joint while walking. The team, led by Minoru Hashimoto, a professor of textile science and technology at Shinshu University in Japan, published the details of their prototype in Smart Materials and Structures, a journal published by the Institute of Physics. Continue reading

Posted in Human Robots

#431006 Adoption of robotics into a ...

VTT Technical Research Centre of Finland studied the implementation of a logistics robot system at the Seinäjoki Central Hospital in South Ostrobothnia. The aim is to reduce transportation costs, improve the availability of supplies and alleviate congestion on hospital hallways by running deliveries around the clock on every day of the week. Joint planning and dialogue between the various occupational groups and stakeholders involved was necessary for a successful change process. Continue reading

Posted in Human Robots

#430649 Robotherapy for children with autism

New Robotherapy for children with autism could reduce patient supervision by therapists.
05.07.2017
Autism treatments and therapies routinely make headlines. With robot enhanced therapies on the rise, often overlooked though, is the mental stress and physical toll the procedures take on therapists. As autism treatments can be taxing on both patient and therapists, few realize the stress and workload of those working with autistic patients.
It is against this backdrop, that researchers from the Vrije Universiteit Brussel are pioneering a new technology to aid behavioural therapy, and one with a very deliberate aspect: they are using robots to boost the basic social learning skills of children with ASD and while doing so, they hope to make the therapists’ job substantially easier.
A study, just published in PALADYN – Journal of Behavioural Robotics examines the use of social robots as tools in clinical situations by addressing the challenge of increasing robot autonomy.
The growing deployment of robot-assisted therapies in recent decades means children with Autism Spectrum Disorder (ASD) can develop and nurture social behaviour and cognitive skills. Learning skills that hold out in real life is the first and foremost goal of all autism therapies, including the Robot-Assisted Therapy (RAT), with effectiveness always considered a key concern. However, this time round the scientists have set off on the additional mission to take the load off the human therapists by letting parts of the intervention be taken over by the supervised yet autonomous robots.
The researchers developed a complete system of robot-enhanced therapy (RET) for children with ASD. The therapy works by teaching behaviours during repeated sessions of interactive games. Since the individuals with ASD tend to be more responsive to feedback coming from an interaction with technology, robots are often used for this therapy. In this approach, the social robot acts as a mediator and typically remains remote-controlled by a human operator. The technique, called Wizard of Oz, requires the robot to be operated by an additional person and the robot is not recording the performance during the therapy. In order to reduce operator workload, authors introduced a system with a supervised autonomous robot – which is able to understand the psychological disposition of the child and use it to select actions appropriate to the current state of the interaction.
Admittedly, robots with supervised autonomy can substantially benefit behavioural therapy for children with ASD – diminishing the therapist workload on the one hand, and achieving more objective measurements of therapy outcomes on the other. Yet, complex as it is, this therapy requires a multidisciplinary approach, as RET provides mixed effectiveness for primary tasks: the turn-taking, joint attention and imitation task comparing to Standard Human Treatment (SHT).
Results are likely to prompt a further development of the robot assisted therapy with increasing robot’s autonomy. With many outstanding conceptual and technical issues yet to tackle –it is definitely the ethical questions that pose one of the major challenges as far as the potential and maximal degree of robot autonomy is concerned.
The article is fully available in open access to read, download and share on De Gruyter Online.
Research was conducted as a part of DREAM (Development of Robot-Enhanced therapy for children with Autism spectrum disorders) project.
DOI: 10.1515/pjbr-2017-0002
Image credit: P.G. Esteban
About the Journal: PALADYN – Journal of Behavioural Robotics is a fully peer-reviewed, electronic-only journal that publishes original, high-quality research on topics broadly related to neuronally and psychologically inspired robots and other behaving autonomous systems.
About De Gruyter Open: De Gruyter Open is a leading publisher of Open Access academic content. Publishing in all major disciplines, De Gruyter Open is home to more than 500 scholarly journals and over 100 books. The company is part of the De Gruyter Group (www.degruyter.com) and a member of the Association of Learned and Professional Society Publishers (ALPSP). De Gruyter Open’s book and journal programs have been endorsed by the international research community and some of the world’s top scientists, including Nobel laureates. The company’s mission is to make the very best in academic content freely available to scholars and lay readers alike.
The post Robotherapy for children with autism appeared first on Roboticmagazine. Continue reading

Posted in Human Robots

#428367 Fusion for Energy signs multi-million ...

Fusion for Energy signs multi-million deal with Airbus Safran Launchers, Nuvia Limited and Cegelec CEM to develop robotics equipment for ITER
The contract for a value of nearly 100 million EUR is considered to be the single biggest robotics deal to date in the field of fusion energy. The state of the art equipment will form part of ITER, the world’s largest experimental fusion facility and the first in history to produce 500 MW. The prestigious project brings together seven parties (China, Europe, Japan, India, the Republic of Korea, the Russian Federation and the USA) which represent 50% of the world’s population and 80% of the global GDP.
The collaboration between Fusion for Energy (F4E), the EU organisation managing Europe’s contribution to ITER, with a consortium of companies consisting of Airbus Safran Launchers (France-Germany), Nuvia Limited (UK) and Cegelec CEM (France), companies of the VINCI Group, will run for a period of seven years. The UK Atomic Energy Authority (UK), Instituto Superior Tecnico (Portugal), AVT Europe NV (Belgium) and Millennium (France) will also be part of this deal which will deliver remotely operated systems for the transportation and confinement of components located in the ITER vacuum vessel.
The contract carries also a symbolic importance marking the signature all procurement packages managed by Europe in the field of remote handling. Carlo Damiani, F4E’s Project Manager for ITER Remote Handling Systems, explained that “F4E’s stake in ITER offers an unparalleled opportunity to companies and laboratories to develop expertise and an industrial culture in fusion reactors’ maintenance.”
Cut-away image of the ITER machine showing the casks at the three levels of the ITER machine. ITER IO © (Remote1 web). Photo Credit: f4e.europa.euIllustration of lorry next to an ITER cask. F4E © (Remote 2 web). Photo Credit: f4e.europa.euAerial view of the ITER construction site, October 2016. F4E © (ITER site aerial Oct). Photo Credit: f4e.europa.eu

Why ITER requires Remote Handling?
Remote handling refers to the high-tech systems that will help us maintain and repair the ITER machine. The space where the bulky equipment will operate is limited and the exposure of some of the components to radioactivity, prohibit any manual intervention inside the vacuum vessel.

What will be delivered through this contract?
The transfer of components from the ITER vacuum vessel to the Hot Cell building, where they will be deposited for maintenance, will need to be carried out with the help of massive double-door containers known as casks. According to current estimates, 15 of these casks will need to be manufactured and in their largest configuration they will measure 8.5 m x 3.7 m x 2.6 m approaching 100 tonnes when transporting the heaviest components. These enormous “boxes”, resembling to a conventional lorry container, will be remotely operated as they move between the different levels and buildings of the machine. Apart from the transportation and confinement of components, the ITER Cask and Plug Remote Handling System will also ensure the installation of the remote handling equipment entering into the vacuum vessel to pick up the components to be removed. The technologies underpinning this system will encompass a variety of high-tech skills and comply with nuclear safety requirements. A proven manufacturing experience in similar fields and the development of bespoke systems to perform mechanical transfers will be essential.

Background information
MEMO: Fusion for Energy signs multi-million deal with Airbus Safran Launchers, Nuvia Limited and Cegelec CEM to develop robotics equipment for ITER
Multimedia
To see how the ITER Remote Handling System will operate click on clip 1 and clip 2
To see the progress of the ITER construction site click here
To take a virtual tour on the ITER construction site click here

Image captions
Cut-away image of the ITER machine showing the casks at the three levels of the ITER machine. ITER IO © (Remote1 web)

Illustration of lorry next to an ITER cask. F4E © (Remote 2 web)

Aerial view of the ITER construction site, October 2016. F4E © (ITER site aerial Oct)

The consortium of companies
The consortium combines the space expertise of Airbus Safran Launchers, adapted to this extreme environment to ensure safe conditions for the ITER teams; with Nuvia comes a wealth of nuclear experience dating back to the beginnings of the UK Nuclear industry. Nuvia has delivered solutions to some of the world’s most complex nuclear challenges; and with Cegelec CEM as a specialist in mechanical projects for French nuclear sector, which contributes over 30 years in the nuclear arena, including turnkey projects for large scientific installations, as well as the realisation of complex mechanical systems.

Fusion for Energy
Fusion for Energy (F4E) is the European Union’s organisation for Europe’s contribution to ITER.
One of the main tasks of F4E is to work together with European industry, SMEs and research organisations to develop and provide a wide range of high technology components together with engineering, maintenance and support services for the ITER project.
F4E supports fusion R&D initiatives through the Broader Approach Agreement signed with Japan and prepares for the construction of demonstration fusion reactors (DEMO).
F4E was created by a decision of the Council of the European Union as an independent legal entity and was established in April 2007 for a period of 35 years.
Its offices are in Barcelona, Spain.
http://www.fusionforenergy.europa.eu
http://www.youtube.com/user/fusionforenergy
http://twitter.com/fusionforenergy
http://www.flickr.com/photos/fusionforenergy

ITER
ITER is a first-of-a-kind global collaboration. It will be the world’s largest experimental fusion facility and is designed to demonstrate the scientific and technological feasibility of fusion power. It is expected to produce a significant amount of fusion power (500 MW) for about seven minutes. Fusion is the process which powers the sun and the stars. When light atomic nuclei fuse together form heavier ones, a large amount of energy is released. Fusion research is aimed at developing a safe, limitless and environmentally responsible energy source.
Europe will contribute almost half of the costs of its construction, while the other six parties to this joint international venture (China, Japan, India, the Republic of Korea, the Russian Federation and the USA), will contribute equally to the rest.
The site of the ITER project is in Cadarache, in the South of France.
http://www.iter.org

For Fusion for Energy media enquiries contact:
Aris Apollonatos
E-mail: aris.apollonatos@f4e.europa.eu
Tel: + 34 93 3201833 + 34 649 179 42
The post Fusion for Energy signs multi-million deal to develop robotics equipment for ITER appeared first on Roboticmagazine. Continue reading

Posted in Human Robots